| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Elisabetta Renzoni | Q55112222 |
| P2093 | author name string | Srihari Veeraraghavan | |
| Angelo de Lauretis | |||
| P2860 | cites work | Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study | Q28200349 |
| Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial | Q28250518 | ||
| Pirfenidone in idiopathic pulmonary fibrosis | Q28267108 | ||
| High-dose acetylcysteine in idiopathic pulmonary fibrosis | Q28283438 | ||
| The 1982 revised criteria for the classification of systemic lupus erythematosus | Q29547225 | ||
| Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus | Q29614922 | ||
| Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data | Q31113801 | ||
| Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus | Q33329033 | ||
| Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients | Q33341941 | ||
| Rituximab treatment of the anti-synthetase syndrome: a retrospective case series | Q45076328 | ||
| Evaluation of interstitial lung disease in mixed connective tissue disease (MCTD). | Q45269838 | ||
| Rapidly progressive fatal interstitial lung disease in a patient with systemic sclerosis | Q46066208 | ||
| Primary Sjögren's syndrome in north east England--a longitudinal study | Q46202118 | ||
| Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. | Q46573264 | ||
| Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis | Q46696172 | ||
| Five-year follow-up study of the prevalence and progression of pulmonary hypertension in systemic lupus erythematosus | Q46815469 | ||
| A long-term study of interstitial lung disease in systemic lupus erythematosus | Q46932521 | ||
| BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis | Q46977247 | ||
| Polymyositis/dermatomyositis-associated lung disease: analysis of a series of 81 patients | Q47737473 | ||
| Mortality and causes of death in primary Sjögren's syndrome: a prospective cohort study | Q47784216 | ||
| Pulmonary manifestations of primary Sjogren's syndrome: a clinical, radiologic, and pathologic study | Q47885073 | ||
| Sjögren's syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary Sjögren's syndrome | Q33359998 | ||
| The overlap of Sjögren's syndrome with other systemic autoimmune diseases | Q33372729 | ||
| Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients | Q33380356 | ||
| Relationship of gold and penicillamine therapy to diffuse interstitial lung disease | Q33481543 | ||
| Pulmonary disease in polymyositis/dermatomyositis: a clinicopathological analysis of 65 autopsy cases | Q33557157 | ||
| Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study | Q33588875 | ||
| Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern | Q33639777 | ||
| Thoracic involvement of systemic lupus erythematosus: clinical, pathologic, and radiologic findings | Q33833672 | ||
| Rheumatoid arthritis (RA)-specific autoantibodies in patients with interstitial lung disease and absence of clinically apparent articular RA. | Q33855193 | ||
| Polymyositis and dermatomyositis (second of two parts) | Q33909233 | ||
| Polymyositis and dermatomyositis (first of two parts) | Q33911013 | ||
| Interstitial lung disease in systemic lupus erythematosus | Q34013368 | ||
| Alveolar hemorrhage in systemic lupus erythematosus: presentation and management | Q34062944 | ||
| Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients | Q34435380 | ||
| Amyopathic dermatomyositis: a review by the Italian Group of Immunodermatology. | Q34492655 | ||
| Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group | Q34523084 | ||
| Cyclophosphamide versus placebo in scleroderma lung disease. | Q34540647 | ||
| Polymyositis and dermatomyositis | Q34542218 | ||
| Diffuse alveolar damage: uncommon manifestation of pulmonary involvement in patients with connective tissue diseases. | Q34555894 | ||
| Sildenafil citrate therapy for pulmonary arterial hypertension | Q34562650 | ||
| Pulmonary complications of polymyositis and dermatomyositis | Q34582326 | ||
| A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma | Q34585630 | ||
| Sulphasalazine and lung toxicity | Q34630190 | ||
| Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? | Q34635659 | ||
| The epidemiology of systemic lupus erythematosus | Q35148597 | ||
| Antisynthetase syndrome | Q35157654 | ||
| Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis | Q35210441 | ||
| Radiological versus histological diagnosis in UIP and NSIP: survival implications. | Q35535697 | ||
| Cigarette smoking and rheumatoid arthritis severity | Q35547371 | ||
| Lung involvement in primary Sjögren's syndrome is mainly related to the small airway disease | Q35548191 | ||
| Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis/dermatomyositis | Q35549233 | ||
| Ten year follow up of pulmonary function in patients with primary Sjögren's syndrome | Q35549609 | ||
| Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach | Q35552142 | ||
| Death rates and causes of death in patients with rheumatoid arthritis: a population-based study | Q47926341 | ||
| Rheumatoid arthritis-related lung diseases: CT findings | Q47976675 | ||
| A multicentre study of 513 Danish patients with systemic lupus erythematosus. I. Disease manifestations and analyses of clinical subsets. | Q50562581 | ||
| Severe restrictive lung disease in systemic sclerosis. | Q50600064 | ||
| Interstitial lung disease in recent onset rheumatoid arthritis. | Q50937957 | ||
| Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease. | Q51683905 | ||
| Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. | Q51713531 | ||
| Acute respiratory failure due to diaphragmatic weakness revealing a polymyositis. | Q51716755 | ||
| Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. | Q51770667 | ||
| Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. | Q52882118 | ||
| The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. | Q52927020 | ||
| Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. | Q53135612 | ||
| Pulmonary manifestations of Sjögren's syndrome. | Q53357839 | ||
| Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis. | Q53488232 | ||
| Interstitial lung disease in primary Sjögren syndrome. | Q53512694 | ||
| CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. | Q53616241 | ||
| Serial chest CT findings in interstitial lung disease associated with polymyositis-dermatomyositis. | Q53631646 | ||
| Pulmonary lesions associated with Sjögren's syndrome: radiographic and CT findings. | Q53634726 | ||
| Methotrexate-Induced Pulmonary Injury: Serial CT findings | Q53640296 | ||
| Clinical and imaging findings of lymphoma in patients with Sjögren syndrome. | Q53645870 | ||
| Nonspecific interstitial pneumonia as pulmonary involvement of primary Sjögren's syndrome. | Q53676244 | ||
| Pulmonary involvement of systemic lupus erythematosus: analysis of 90 necropsies. | Q54052789 | ||
| Use of intermittent, intravenous cyclophosphamide for idiopathic pulmonary fibrosis | Q54059359 | ||
| Sjögren's syndrome | Q55921808 | ||
| The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France | Q56978153 | ||
| Immunosuppressive therapy in lupus- and mixed connective tissue disease–associated pulmonary arterial hypertension: A retrospective analysis of twenty-three cases | Q56978175 | ||
| High-resolution CT imaging of the lung for patients with primary Sjögren’s syndrome | Q57991215 | ||
| Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. | Q43227321 | ||
| Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study | Q43764381 | ||
| Interstitial lung disease in systemic sclerosis: a simple staging system | Q43841678 | ||
| Intravenous immunoglobulin therapy of lupus pneumonitis | Q43985264 | ||
| Systemic lupus erythematosus in a multiethnic US Cohort LUMINA XLVIII: factors predictive of pulmonary damage | Q44148062 | ||
| Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases | Q44301323 | ||
| Rituximab treatment of pulmonary arterial hypertension associated with systemic lupus erythematosus: a case report | Q44550960 | ||
| Clinical differences between idiopathic and scleroderma-related pulmonary hypertension | Q44610192 | ||
| Therapy with intermittent pulse cyclophosphamide for pulmonary hypertension associated with systemic lupus erythematosus | Q44782989 | ||
| Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. | Q44934375 | ||
| ??? | Q28215495 | ||
| Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis | Q35553923 | ||
| Catastrophic antiphospholipid syndrome: where do we stand? | Q35607279 | ||
| Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. | Q35771091 | ||
| Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis | Q35794369 | ||
| The respiratory system in connective tissue disorders | Q36117547 | ||
| Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. | Q36145795 | ||
| Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease | Q36157808 | ||
| Tolerability and safety of rituximab (MabThera). | Q36212992 | ||
| Risk factors for the development of rheumatoid arthritis | Q36502903 | ||
| Sjogren's syndrome is associated with and not secondary to systemic sclerosis | Q36551164 | ||
| Leflunomide-related lung injury in patients with rheumatoid arthritis: imaging features | Q36618003 | ||
| Recent advances in the treatment of interstitial lung disease in patients with polymyositis/dermatomyositis | Q36703820 | ||
| The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. | Q36773107 | ||
| Pulmonary function tests in connective tissue disease | Q36925854 | ||
| Computed tomographic imaging in connective tissue diseases | Q36925857 | ||
| Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease | Q36932914 | ||
| Pulmonary arterial hypertension: a rare complication of primary Sjögren syndrome: report of 9 new cases and review of the literature | Q36943691 | ||
| Pulmonary complications of tumor necrosis factor-targeted therapy | Q37345155 | ||
| Pathologic and radiologic differences between idiopathic and collagen vascular disease-related usual interstitial pneumonia | Q37405160 | ||
| Dyspnoea in a young woman with active systemic lupus erythematosus | Q37541564 | ||
| Respiratory manifestations of systemic lupus erythematosus: old and new concepts | Q37547373 | ||
| Management of fibrosing alveolitis with polymyositis dermatomyositis | Q38037199 | ||
| Mortality in systemic lupus erythematosus | Q38467155 | ||
| Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis | Q39296891 | ||
| Racial differences in scleroderma among women in Michigan | Q39444053 | ||
| Clinical manifestations of systemic sclerosis | Q39463072 | ||
| Increased Risk of Lymphoma in Sicca Syndrome | Q39632164 | ||
| Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement | Q39641547 | ||
| Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology | Q40098741 | ||
| Pulmonary disease in polymyositis/dermatomyositis | Q40188390 | ||
| Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. | Q40447750 | ||
| Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors | Q40532147 | ||
| Interstitial lung disease in polymyositis and dermatomyositis: Clinical course and response to treatment | Q40593461 | ||
| Polymyositis-dermatomyositis-associated interstitial lung disease | Q40594417 | ||
| Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis | Q40606173 | ||
| Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome | Q40634492 | ||
| Pulmonary alveolar hemorrhage in systemic lupus erythematosus | Q40777936 | ||
| Drug-induced alveolitis caused by salazosulfapyridine | Q40784055 | ||
| Outcome of subjects with idiopathic pulmonary fibrosis who fail corticosteroid therapy. Implications for further studies | Q41094710 | ||
| Methotrexate-related pulmonary complications in rheumatoid arthritis | Q41275873 | ||
| Diffuse alveolar hemorrhage and systemic lupus erythematosus. Clinical presentation, histology, survival, and outcome | Q41507484 | ||
| The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: A prospective study | Q42613594 | ||
| Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil | Q43218254 | ||
| P433 | issue | 1 | |
| P921 | main subject | interstitial lung disease | Q1153419 |
| connective tissue | Q25615 | ||
| P304 | page(s) | 53-82 | |
| P577 | publication date | 2011-01-01 | |
| P1433 | published in | Chronic Respiratory Disease | Q5113956 |
| P1476 | title | Review series: Aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ? | |
| P478 | volume | 8 |
| Q35600363 | Airway-centered interstitial fibrosis: etiology, clinical findings and prognosis |
| Q42699610 | An Overview of the Extraarticular Involvement in Rheumatoid Arthritis and its Management |
| Q36745669 | Association between anti-TNF-α therapy and interstitial lung disease |
| Q47957333 | CD11b+Gr-1dim Tolerogenic Dendritic Cell-Like Cells Are Expanded in Interstitial Lung Disease in SKG Mice. |
| Q33915673 | Characterisation of patients with interstitial pneumonia with autoimmune features |
| Q38044387 | Circulating biomarkers of interstitial lung disease in systemic sclerosis |
| Q53070534 | Comparison of short-term outcomes for connective tissue disease-related interstitial lung disease and idiopathic pulmonary fibrosis after lung transplantation. |
| Q27024062 | Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials |
| Q41816049 | Desquamative interstitial pneumonitis in a patient with systemic lupus erythematosus. |
| Q43249004 | Difficulties in diagnosis of systemic sclerosis-related interstitial lung disease |
| Q38075503 | Glucocorticoids in rheumatoid arthritis. |
| Q91218777 | Idiopathic and immune-related pulmonary fibrosis: diagnostic and therapeutic challenges |
| Q92913411 | Impact of a systematic evaluation of connective tissue disease on diagnosis approach in patients with interstitial lung diseases |
| Q35151957 | Influence of autoimmune biomarkers on interstitial lung diseases: A tertiary referral center based case-control study. |
| Q33824245 | Interpretation of autoantibody positivity in interstitial lung disease and lung-dominant connective tissue disease |
| Q47650949 | Interstitial Pneumonia with Autoimmune Features: Overview of proposed criteria and recent cohort characterization |
| Q47372819 | Interstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review |
| Q50610061 | Is lung transplantation a valuable therapeutic option for patients with pulmonary polymyositis? Experiences from the Leuven transplant cohort. |
| Q92578896 | Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 5. Connective Tissue Disease Associated Interstitial Lung Disease |
| Q92914293 | Mechanisms of lung disease development in rheumatoid arthritis |
| Q38220769 | Molecular biomarkers in interstitial lung diseases. |
| Q45167705 | Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study |
| Q34537674 | Nonspecific interstitial pneumonia: clinical associations and outcomes |
| Q38688705 | Novel Assessment of Interstitial Lung Disease Using the "Computer-Aided Lung Informatics for Pathology Evaluation and Rating" (CALIPER) Software System in Idiopathic Inflammatory Myopathies |
| Q36726418 | Outcome Measures for Clinical Trials in Interstitial Lung Diseases |
| Q26830824 | Pivotal roles of GM-CSF in autoimmunity and inflammation |
| Q37979249 | Potential significance of telocytes in the pathogenesis of lung diseases |
| Q38642378 | Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis. |
| Q41966900 | Rheumatoid arthritis associated pulmonary hypertension: Clinical challenges reflecting the diversity of pathophysiology. |
| Q51144192 | Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics--a large multicentre UK study. |
| Q33737250 | Role of Autoantibodies in the Diagnosis of Connective-Tissue Disease ILD (CTD-ILD) and Interstitial Pneumonia with Autoimmune Features (IPAF). |
| Q92120400 | Squawks in interstitial lung disease prevalence and causes in a cohort of one thousand patients |
| Q26777295 | State of the art in the diagnosis and management of interstitial lung disease |
| Q37934752 | Telocyte morphologies and potential roles in diseases |
| Q41642420 | The COPD Assessment Test as a Prognostic Marker in Interstitial Lung Disease |
| Q34569852 | The benefits of exercise training in interstitial lung disease: protocol for a multicentre randomised controlled trial |
| Q26861557 | The multifaceted aspects of interstitial lung disease in rheumatoid arthritis |
| Q46770755 | Transitions to different patterns of interstitial lung disease in scleroderma with and without treatment. |
| Q87580726 | [Acute on chronic respiratory failure in interstitial pneumonias] |
Search more.